The latest price target for Medicus Pharma (NASDAQ:MDCX) was reported by D. Boral Capital on March 19, 2026. The analyst firm set a price target for $27.00 expecting MDCX to rise to within 12 months (a possible 6406.02% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Medicus Pharma (NASDAQ:MDCX) was provided by D. Boral Capital, and Medicus Pharma maintained their buy rating.

There is no last upgrade for Medicus Pharma

There is no last downgrade for Medicus Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medicus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medicus Pharma was filed on March 19, 2026 so you should expect the next rating to be made available sometime around March 19, 2027.

While ratings are subjective and will change, the latest Medicus Pharma (MDCX) rating was a maintained with a price target of $27.00 to $27.00. The current price Medicus Pharma (MDCX) is trading at is $0.42, which is out of the analyst’s predicted range.